查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602396

急性冠状动脉症候群市场：按类型、产品和最终用户划分 - 全球预测 2025-2030

Acute Coronary Syndrome Market by Type (Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), Unstable Angina), Offering (Blood Tests, Imaging, Stress Test), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，急性冠状动脉症候群市场价值为18.2亿美元，预计到2024年将达到19.4亿美元，复合年增长率为6.76%，到2030年将达到28.9亿美元。

急性冠状动脉症候群(ACS) 包括多种​​涉及心臟血流量突然减少的病症，通常以胸痛和不适为特征。 ACS 包括心肌梗塞和不稳定型心绞痛，其严重性和日益增加的盛行率需要准确的市场分析。 ACS 的早期诊断和治疗对于降低发病率和死亡率至关重要，这凸显了先进诊断工具和治疗性介入的应用。最终用途范围主要包括医院、门诊医疗中心和配备新技术以有效对抗 ACS 的诊断实验室。该市场受到老年人口成长、生活方式相关风​​险因素发生率增加以及基于生物标记和就地检验等医疗技术进步的强烈影响。个人化医疗的进步、预测分析人工智慧的整合以及支架技术和药物治疗的创新都存在机会。成长的障碍包括治疗成本上升、严格的法律规范以及发展中地区的准入有限。为了利用这些机会，公司可以专注于策略伙伴关係关係，探索用于风险评估的基因分析，并开拓适合新兴市场的具有成本效益的解决方案。非侵入性诊断、穿戴式监测设备和改进的药物传输系统等领域的创新可能会蓬勃发展。随着对卓越的患者治疗效果和医疗保健服务效率的不断追求，市场竞争激烈，颠覆的时机已经成熟。公司还必须适应向基于价值的护理模式的转变，强调整体患者体验和长期健康效益。透过利用技术并专注于以患者为中心的创新，相关人员可以克服挑战并有效推动 ACS 领域的市场成长。

主要市场统计
基准年[2023] 18.2亿美元
预测年份 [2024] 19.4亿美元
预测年份 [2030] 28.9亿美元
复合年增长率（%） 6.76%

市场动态：快速发展的急性冠状动脉症候群市场的关键市场洞察

供应和需求的动态交互作用正在改变急性冠状动脉症候群市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球心血管疾病盛行率不断上升
    • 倾向于疾病的早期诊断和治疗
    • 药物发现和药物开发流程的增加
  • 市场限制因素
    • 急性冠状动脉症候群的治疗费用上涨
  • 市场机会
    • 急性冠状动脉症候群治疗进展
    • 持续研究和开发以改善急性冠状动脉症候群的诊断设备和治疗方法
  • 市场挑战
    • 急性冠状动脉症候群药物和器械核准的严格监管要求

波特五力：驾驭急性冠状动脉症候群市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解急性冠状动脉症候群市场的外部影响

外部宏观环境因素在塑造急性冠状动脉症候群市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解急性冠状动脉症候群市场的竞争格局

对急性冠状动脉症候群市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵急性冠状动脉症候群市场供应商的绩效评估

FPNV 定位矩阵是评估急性冠状动脉症候群市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了急性冠状动脉症候群市场的成功之路

急性冠状动脉症候群市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球心血管疾病盛行率增加
      • 疾病的早​​期诊断和治疗趋势
      • 改进药物发现和开发流程
    • 抑制因素
      • 急性冠状动脉症候群的治疗费用上涨
    • 机会
      • 急性冠状动脉症候群的治疗进展
      • 正在进行的研究和开发旨在改进急性冠状动脉症候群的诊断设备和治疗
    • 任务
      • 核准治疗急性冠状动脉症候群的药物和器械的严格监管要求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章急性冠状动脉症候群市场：依类型

  • 非中心抬高型心肌梗塞 (NSTEMI)
  • ST 段上升型心肌梗塞 (STEMI)
  • 不稳定型心绞痛

第七章急性冠状动脉症候群市场：透过提供

  • 验血
  • 影像
  • 压力测试

第八章急性冠状动脉症候群市场：依最终用户分类

  • 学术机构
  • 诊断中心
  • 医院/诊所

第九章美洲急性冠状动脉症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区急性冠状动脉症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲急性冠状动脉症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • bioMerieux SA
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Johnson & Johnson Service, Inc.
  • Koninklijke Philips NV
  • Medtronic PLC
  • Merck & Co, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Siemens AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C99761

The Acute Coronary Syndrome Market was valued at USD 1.82 billion in 2023, expected to reach USD 1.94 billion in 2024, and is projected to grow at a CAGR of 6.76%, to USD 2.89 billion by 2030.

Acute Coronary Syndrome (ACS) encompasses a spectrum of conditions associated with sudden, reduced blood flow to the heart, typically characterized by chest pain or discomfort. It includes conditions such as myocardial infarction and unstable angina, demanding precise market analysis due to its critical nature and increasing prevalence. The necessity of early diagnosis and treatment of ACS is vital to reduce morbidity and mortality rates, highlighting the application of advanced diagnostic tools and therapeutic interventions. The end-use scope primarily involves hospitals, ambulatory care centers, and diagnostic laboratories armed with emerging technologies to combat ACS effectively. The market is strongly influenced by the growing geriatric population, increasing incidence of lifestyle-related risk factors, and advancements in medical technology such as biomarker-based tests and point-of-care testing. Opportunities lie in the development of personalized medicine, integration of artificial intelligence for predictive analytics, and innovations in stent technology and pharmacotherapy. Barriers to growth include high costs of treatment, stringent regulatory frameworks, and limited accessibility in developing regions. To capitalize on these opportunities, companies can focus on strategic partnerships, research in genetic profiling for risk assessment, and the development of cost-effective solutions tailored to emerging markets. Innovation can flourish in areas like non-invasive diagnostic methods, wearable monitoring devices, and improved drug delivery systems. The market nature is highly competitive yet ripe for disruption with a constant push towards superior patient outcomes and efficiency in healthcare delivery. Companies must also adapt to the shift towards value-based care models, emphasizing overall patient experiences and long-term health benefits. By leveraging technology and focusing on patient-centric innovation, stakeholders can navigate the challenges and propel market growth in the ACS sector effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.82 billion
Estimated Year [2024] USD 1.94 billion
Forecast Year [2030] USD 2.89 billion
CAGR (%) 6.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Coronary Syndrome Market

The Acute Coronary Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cardiovascular diseases worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Rise in drug discovery and drug development process
  • Market Restraints
    • High cost of treatment of acute-coronary-syndrome
  • Market Opportunities
    • Advancements in the treatment of acute-coronary-syndrome
    • Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
  • Market Challenges
    • Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Coronary Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Coronary Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Coronary Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Coronary Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Coronary Syndrome Market

A detailed market share analysis in the Acute Coronary Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Coronary Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Coronary Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Coronary Syndrome Market

A strategic analysis of the Acute Coronary Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Coronary Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, bioMerieux SA, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson Service, Inc., Koninklijke Philips N.V., Medtronic PLC, Merck & Co, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Siemens AG, Terumo Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Coronary Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), and Unstable Angina.
  • Based on Offering, market is studied across Blood Tests, Imaging, and Stress Test.
  • Based on End User, market is studied across Academic Institutes, Diagnostic Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Rise in drug discovery and drug development process
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment of acute-coronary-syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the treatment of acute-coronary-syndrome
      • 5.1.3.2. Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Coronary Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Non-St-Elevation Myocardial Infarction (NSTEMI)
  • 6.3. St-Elevation Myocardial Infarction (STEMI)
  • 6.4. Unstable Angina

7. Acute Coronary Syndrome Market, by Offering

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Imaging
  • 7.4. Stress Test

8. Acute Coronary Syndrome Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Institutes
  • 8.3. Diagnostic Centers
  • 8.4. Hospitals & Clinics

9. Americas Acute Coronary Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Coronary Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Coronary Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Baxter International, Inc.
  • 5. Bayer AG
  • 6. bioMerieux SA
  • 7. Boehringer Ingelheim International GmbH
  • 8. Boston Scientific Corporation
  • 9. DAIICHI SANKYO COMPANY, LIMITED
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Gilead Sciences, Inc.
  • 14. Johnson & Johnson Service, Inc.
  • 15. Koninklijke Philips N.V.
  • 16. Medtronic PLC
  • 17. Merck & Co, Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals Inc.
  • 21. Sanofi S.A.
  • 22. Siemens AG
  • 23. Terumo Corporation
  • 24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ACUTE CORONARY SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CORONARY SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CORONARY SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE CORONARY SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION (STEMI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023